Glaxo’s Paxil Increases Risk of Birth Defects
Glaxo’s Paxil Raises Possibility of Birth Defects
(January 25, 2011) Recent studies showed that Paxil, an anti-depressant drug manufactured by GlaxoSmithKline, increased the danger of birth defects for pregnant women all through their very first trimester.
Researchers claimed that females who have been taking Paxil are one and a half to two times more likely to get a infant with cardiovascular defects compared with a population of pregnant women of all ages who failed to take antidepressant medicines. In addition, an infant may also have a life-threatening birth defects for example numerous organ failure and death.
According to the study, most of the heart defects come with atrial and ventricular septal defects, that happen to be characterized by holes in the walls of the chambers of the heart. Care for such malformations may range from minor to severe, with the worst case requiring surgical repair. Researchers said that such ailments may prove fatal.
They said that even though babies who make it through the initial trauma may eventually develop permanent physical damage such as hearing and speech defects as well as cognitive deterioration, which can result in developmental delays and neurological deficits. In addition, researchers were also concerned about selective serotonin reuptake inhibitors. On the contrary, despite all the deaths and lawsuits filed against the drug, Paxil continues to retain the FDA approval.
Latest update on Paxil side effects shows that the antidepressant drug does not help patients with mild to severe depression much more than an inactive placebo. Based on a meta-analysis, Paxil has lesser effect to halt depression and even causes the patient to become more depressed and suicidal. Experts said that these studies must prompt Glaxo and FDA to weigh the harmful effects of the drug.
For more information please visit www.seedol.com
Article Source: i2 Article Directory (www.i2articledirectory.info)